A new combination treatment designed specifically for each patient's unique tumor has shown it can significantly reduce the risk of melanoma returning after surgery. In a Phase 3 clinical trial called INTerpath-001, researchers found that intismeran autogene, an mRNA-based personalized cancer vaccine made by Merck and Moderna, combined with the immunotherapy drug KEYTRUDA (pembrolizumab), reduced recurrence risk and the spread of cancer to distant sites compared to KEYTRUDA alone in patients with high-risk melanoma.

What Makes This Treatment Different?

Unlike traditional cancer drugs that work the same way for every patient, intismeran autogene is custom-made for each person. Doctors analyze the unique mutations in a patient's tumor to identify what researchers call its "fingerprint." The vaccine then contains genetic instructions for up to 34 different neoantigens, which are abnormal proteins that appear only on that individual's cancer cells. When injected, the mRNA teaches the immune system to recognize and attack those specific cancer markers.

The INTerpath-001 trial enrolled 1,137 patients with completely resected stage IIB through IV cutaneous melanoma who had not received prior systemic therapy. At an interim analysis, the combination of intismeran and KEYTRUDA demonstrated statistically significant improvements in both recurrence-free survival and distant metastasis-free survival compared to KEYTRUDA alone. The safety profile was consistent with previous studies, and no new safety concerns emerged.

Why Does This Matter for Melanoma Patients?

This represents the first Phase 3 positive result for an individualized neoantigen therapy and the first mRNA-based cancer therapy to show meaningful improvement over a standard-of-care immunotherapy in the adjuvant setting, meaning treatment given after surgery to prevent recurrence. The findings build on earlier Phase 2b data from the KEYNOTE-942 trial, which showed a 49% reduction in the risk of recurrence or death and a 59% reduction in the risk of distant metastasis or death when patients received the combination compared to KEYTRUDA alone.

"Today's results represent a landmark moment for adjuvant melanoma treatment. This is the first Phase 3 study to show that intismeran, a treatment designed based on the unique mutational 'fingerprint' of a patient's own tumor, given in combination with pembrolizumab can reduce the risk of recurrence or death in patients with completely resected stage IIB-IV melanoma compared to KEYTRUDA alone," said Professor Georgina Long, the study's principal investigator and medical director of Melanoma Institute Australia.

Professor Georgina Long, Medical Director of Melanoma Institute Australia and Chair of Melanoma Medical Oncology and Translational Research at the University of Sydney

How Does Personalized Immunotherapy Work?

The approach combines two powerful cancer-fighting strategies. First, the mRNA vaccine trains the immune system to recognize cancer-specific mutations that are unique to each patient's tumor. Second, KEYTRUDA is a checkpoint inhibitor, a type of immunotherapy that removes the "brakes" cancer cells use to hide from the immune system. Together, they work to activate and enhance the body's natural defenses against melanoma cells.

Steps to Understanding Your Treatment Options

• Tumor Analysis: If you have high-risk melanoma, your surgical sample is analyzed to identify the unique mutations specific to your cancer.
• Personalized Vaccine Creation: Based on those mutations, a custom mRNA vaccine is manufactured with instructions for your immune system to recognize up to 34 different cancer markers.
• Combined Treatment: The vaccine is given every three weeks for up to nine doses alongside KEYTRUDA infusions every six weeks for approximately one year.
• Ongoing Monitoring: Your medical team tracks your recurrence-free survival and watches for any side effects throughout and after treatment.

The companies plan to present detailed data at an upcoming international medical meeting and will engage with regulatory authorities about filing for approval. The INTerpath clinical development program currently includes nine Phase 2 and Phase 3 trials testing intismeran in combination with KEYTRUDA and other therapies across multiple cancer types, including non-small cell lung cancer, bladder cancer, and renal cell carcinoma. Additional studies are exploring the vaccine in pancreatic cancer, gastric cancer, and early-stage lung cancer.

"These Phase 3 findings represent a pivotal moment for the field of cancer research. For many years, the idea of creating an mRNA treatment designed specifically for an individual patient's cancer was aspirational. We are now helping turn that vision into a reality," said Stéphane Bancel, CEO of Moderna.

Stéphane Bancel, CEO of Moderna

What About Side Effects?

In the INTerpath-001 trial, the safety profiles of intismeran and KEYTRUDA were consistent with what researchers had observed in previous studies of the combination. No new safety signals were detected, meaning the side effect profile was as expected and manageable. However, like all immunotherapies, KEYTRUDA can cause immune-related side effects that require careful monitoring by your oncology team.

This breakthrough represents a shift toward more personalized cancer medicine, where treatments are tailored to the specific biology of each patient's tumor rather than using a one-size-fits-all approach. As these results move toward regulatory review, they may establish a new standard of care for patients with high-risk resected melanoma.